M
Markus Hoffmann
Researcher at German Primate Center
Publications - 155
Citations - 23747
Markus Hoffmann is an academic researcher from German Primate Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 30, co-authored 103 publications receiving 14853 citations. Previous affiliations of Markus Hoffmann include University of Veterinary Medicine Hanover & University of Veterinary Medicine Vienna.
Papers
More filters
Journal ArticleDOI
TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1.
Pawel Zmora,Markus Hoffmann,Heike Kollmus,Anna-Sophie Moldenhauer,Olga Danov,Armin Braun,Michael Winkler,Klaus Schughart,Klaus Schughart,Stefan Pöhlmann,Stefan Pöhlmann +10 more
TL;DR: The results suggest that TMPRSS11A could promote FLUAV spread in target cells and that HA-activating TTSPs exhibit differential sensitivity to blockade by cellular serine protease inhibitors.
Journal ArticleDOI
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Matthew Mahoney,Vishnu C. Damalanka,Michael A Tartell,Michael A Tartell,Dong Hee Chung,André Luiz Lourenço,Dustin Pwee,Anne E. Mayer Bridwell,Markus Hoffmann,Markus Hoffmann,Jorine Voss,Partha Karmakar,Nurit P. Azouz,Andrea M. Klingler,Paul W. Rothlauf,Paul W. Rothlauf,Cassandra E Thompson,Melody Lee,Lidija Klampfer,Christina L. Stallings,Marc E. Rothenberg,Stefan Pöhlmann,Stefan Pöhlmann,Sean P. J. Whelan,Anthony J. O’Donoghue,Charles S. Craik,James W. Janetka +26 more
TL;DR: In this article, the authors used rational structure-based drug design (SBDD) coupled with substrate specificity screening of TMPRSS2 to discover covalent small-molecule ketobenzothiazole (kbt) inhibitors which are structurally distinct from and have significantly improved activity over the existing known inhibitors Camostat and Nafamostat.
Journal ArticleDOI
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.
Prerna Arora,Prerna Arora,Amy Kempf,Amy Kempf,Inga Nehlmeier,Luise Graichen,Luise Graichen,Anzhalika Sidarovich,Anzhalika Sidarovich,Martin Sebastian Winkler,Sebastian R. Schulz,Hans-Martin Jäck,Metodi V. Stankov,Georg M. N. Behrens,Stefan Pöhlmann,Stefan Pöhlmann,Markus Hoffmann,Markus Hoffmann +17 more
Journal ArticleDOI
A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry.
Markus Hoffmann,Lisa Crone,Erik Dietzel,Jennifer Paijo,Mariana González-Hernández,Inga Nehlmeier,Ulrich Kalinke,Stephan Becker,Stefan Pöhlmann +8 more
TL;DR: It is found that position 544 is an important determinant of EBOV infectivity for both NHP and certain human target cells, and an amino acid exchange that was acquired during the epidemic and that was not observed in previously circulating viruses, increases viral entry into diverse target cells.
Journal ArticleDOI
Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines
Anne Frentzen,Kathrin Hüging,Julia Bitzegeio,Martina Friesland,Sibylle Haid,Juliane Gentzsch,Markus Hoffmann,Dirk Lindemann,Gert Zimmer,Florian Zielecki,Friedemann Weber,Eike Steinmann,Thomas Pietschmann +12 more
TL;DR: These data strongly advocate transgenic approaches of crucial human HCV cofactors to establish an immunocompetent small animal model and exclude that constitutive or virus-induced expression of dominant restriction factors prevents propagation of HCV in these cell types, which has important implications for HCV tissue and species tropism.